Английская Википедия:Frunevetmab

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug

Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.[1]

It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[1]

Frunevetmab is the international nonproprietary name (INN).[2]

Clinical usage

Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[1] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[1]

Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[1][3]

The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[1]

History

In February 2021, Frunevetmab was approved for medical use in the European Union.[3]

In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[1][4]

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [5]

See also

References

Шаблон:Reflist Шаблон:HHS content

Bibliography

External links

Шаблон:Analgesics Шаблон:Portal bar


Шаблон:Veterinary-med-stub

  1. 1,0 1,1 1,2 1,3 1,4 1,5 1,6 Шаблон:Cite press release Шаблон:PD-notice
  2. Шаблон:Cite journal
  3. 3,0 3,1 Ошибка цитирования Неверный тег <ref>; для сносок Solensia EPAR не указан текст
  4. Шаблон:Cite web
  5. Шаблон:Cite web